Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 9/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2272178 | 0.86 | ELANE (0.56) | NOTUMELANESMN1; SMN2 | |
| SCHEMBL984085 | 0.82 | NOTUM (0.64) | NOTUMELANEKMT2A | |
| SCHEMBL8053624 | 0.82 | ELANE (0.49) | NOTUMELANESMN1; SMN2 | |
| SCHEMBL8229059 | 0.82 | NOTUM (0.51) | NOTUMELANETP53MEN1KMT2A | |
| SCHEMBL4152986 | 0.82 | ELANE (0.50) | NOTUMELANE | |
| SCHEMBL27716691 | 0.82 | NOTUM (0.53) | NOTUMELANEHPGDMEN1KMT2A | |
| SCHEMBL5758047 | 0.81 | ELANE (0.56) | PDE4BPDE4DNOTUMELANENPC1 | |
| SCHEMBL1604233 | 0.81 | KDM4E (0.49) | NOTUMELANESMN1; SMN2 | |
| SCHEMBL5758051 | 0.80 | ELANE (0.58) | PDE4BPDE4DNOTUMELANENPC1 | |
| SCHEMBL4281376 | 0.80 | PDE4B (0.43) | PDE4BPDE4DNOTUMELANENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105239-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105239-A1 | 2-PYRIDINE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | SERPINB1, ELANE, MPO | PDE4B 348/4885PDE4D 487/4885NOTUM 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.